Clinical Trial Update: A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the onset and duration of action of AC-170 0.24% versus vehicle for allergic conjunctivitis was completed and results were p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• AC-170 0.24% (AC-170)

Snippet

Sponsor: Aciex Therapeutics, Inc. | Conditions: Allergic Conjunctivitis | Phase 3 | Status: COMPLETED | Results posted: 2017-10-10